Skip to main
RCEL

RCEL Stock Forecast & Price Target

RCEL Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AVITA Medical is a promising company with an innovative and approved product, the RECELL system, which has a positive outlook in the US market. While the company faces risks such as Clinical/Regulatory, Partnership and Financial, Commercial, Legal and Intellectual Property, and Market Share, the recent BARDA contract is a strategic positive in reinforcing government relationships and validating RECELL's role in emergency care. The company's multi-center study and real-world use cases highlight the product's effectiveness in wound care preparation, and the addition of PermeaDerm further strengthens their comprehensive platform approach. With a focus on functional recovery and patient-centric metrics, AVITA is positioning itself as a leader in integrated wound care solutions, and potential updates from future medical conferences could further validate their platform and support broader adoption in burn centers and hospital systems.

Bears say

AVITA Medical is facing significant challenges due to its reliance on a single product, the RECELL system, which predominantly relies on episodic government support for revenue. The limited committed revenue and uncertain economic impact of government contracts suggest minimal near-term profitability. The long-term outlook depends on the company's ability to translate clinical success into sustained procedural growth and revenue acceleration, which is uncertain given the presence of multiple risk factors, including regulatory, financial, and market share risks. However, recent strategic moves such as the refinancing of debt and the removal of key constraints on utilization may provide some operational tailwinds in the short term, but the ultimate success of the company will depend on its ability to drive commercial adoption and diversify its product portfolio to lessen its reliance on government support.

RCEL has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AVITA Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AVITA Medical Inc (RCEL) Forecast

Analysts have given RCEL a Strong Buy based on their latest research and market trends.

According to 3 analysts, RCEL has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AVITA Medical Inc (RCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.